NextCure (NXTC) News Today → This is the best new way to score with AI (From Weiss Ratings) (Ad) Free NXTC Stock Alerts $1.66 +0.07 (+4.40%) (As of 05/15/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 7, 2024 | americanbankingnews.comHC Wainwright Reiterates Buy Rating for NextCure (NASDAQ:NXTC)May 7, 2024 | americanbankingnews.comNeedham & Company LLC Reiterates "Buy" Rating for NextCure (NASDAQ:NXTC)May 4, 2024 | markets.businessinsider.comBuy Rating Affirmed for NextCure Amid Promising Oncology Treatment Prospects and Solid FinancialsMay 2, 2024 | investorplace.comNXTC Stock Earnings: NextCure Misses EPS for Q1 2024May 2, 2024 | globenewswire.comNextCure Provides Business Update and Reports First Quarter 2024 Financial ResultsApril 24, 2024 | globenewswire.comNextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024April 8, 2024 | markets.businessinsider.comPromising Clinical Outlook for NextCure’s Novel ADC LNCB74 Spurs Buy RatingApril 8, 2024 | globenewswire.comNextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024April 4, 2024 | globenewswire.comNextCure Appoints Dr. Rakesh Dixit to Scientific Advisory BoardApril 2, 2024 | globenewswire.comNextCure to Present at 23rd Annual Needham Virtual Healthcare ConferenceMarch 27, 2024 | marketbeat.comNextCure, Inc. (NASDAQ:NXTC) Short Interest UpdateNextCure, Inc. (NASDAQ:NXTC - Get Free Report) saw a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 839,700 shares, a growth of 579.9% from the February 29th total of 123,500 shares. Based on an average daily trading volume, of 229,500 shares, the short-interest ratio is presently 3.7 days. Approximately 4.0% of the company's stock are sold short.March 27, 2024 | finance.yahoo.comWill NextCure (NASDAQ:NXTC) Spend Its Cash Wisely?March 23, 2024 | investorplace.comWall Street's Favorite Penny Stocks? 7 Names That Could Make You Filthy RichMarch 22, 2024 | markets.businessinsider.comPromising Clinical Trial Results for NextCure’s NC410 Bolster Buy RatingMarch 22, 2024 | marketbeat.comHC Wainwright Boosts NextCure (NASDAQ:NXTC) Price Target to $8.00HC Wainwright boosted their price target on NextCure from $5.00 to $8.00 and gave the company a "buy" rating in a research note on Friday.March 21, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Femasys (FEMY) and NextCure (NXTC)March 21, 2024 | marketwatch.comNextCure to Cut 37% of Jobs, Will Narrow Focus on Drug CandidatesMarch 21, 2024 | bizjournals.comMd. biopharma lays off staff, pauses manufacturing to preserve cashMarch 21, 2024 | globenewswire.comNextCure Provides Business Update and Reports Full Year 2023 Financial ResultsMarch 5, 2024 | globenewswire.comNextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science AdvancesJanuary 18, 2024 | finance.yahoo.comNextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway DisordersDecember 28, 2023 | benzinga.comNextCure Stock (NASDAQ:NXTC) Dividends: History, Yield and DatesDecember 25, 2023 | finance.yahoo.comHere's Why NextCure, Inc. (NXTC) Looks Ripe for Bottom FishingDecember 21, 2023 | finance.yahoo.comNextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord InjuryDecember 15, 2023 | finance.yahoo.comNextCure (NXTC) Down on Shelving Plans to Develop CandidateDecember 15, 2023 | markets.businessinsider.comBuy Rating Justified by NextCure’s Promising Developments in MSS-CRC Treatment and Strategic Pipeline ShiftDecember 15, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: NextCure (NXTC) and Achieve Life Sciences (ACHV)December 14, 2023 | msn.comNextCure stock falls 20% amid program shutdown, business updateDecember 14, 2023 | marketwatch.comNextCure Shares Fall 26% After Halting Development of One Drug CandidateDecember 14, 2023 | finance.yahoo.comNextCure Provides Year-End Clinical Pipeline UpdatesNovember 20, 2023 | finance.yahoo.comNextCure to Present at the 35th Annual Piper Sandler Healthcare ConferenceNovember 15, 2023 | finance.yahoo.comNextCure Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AMLNovember 12, 2023 | morningstar.comNextCure Inc NXTCNovember 7, 2023 | msn.comAll You Need to Know About NextCure, Inc. (NXTC) Rating Upgrade to BuyNovember 2, 2023 | finance.yahoo.comNextCure Provides Business Update and Reports Third Quarter 2023 Financial ResultsNovember 2, 2023 | finance.yahoo.comNextCure Inc (NXTC) Reports Q3 2023 Financial ResultsOctober 19, 2023 | finance.yahoo.comWe Think NextCure (NASDAQ:NXTC) Needs To Drive Business Growth CarefullyOctober 17, 2023 | finance.yahoo.comPreclinical Data Demonstrate Anti-Siglec-15 Treatment Reduced Bone Loss and Enhanced Bone Quality in Mice with Moderate-to-Severe Osteogenesis Imperfecta (OI)October 5, 2023 | msn.comNextcure (NXTC) Price Target Increased by 26.67% to 6.46September 26, 2023 | benzinga.comNextCure Presents Preclinical Data on NC181, a Novel Therapeutic Candidate Targeting ApoE4, for the Treatment of Alzheimer's DiseaseSeptember 26, 2023 | finance.yahoo.comNextCure Presents Preclinical Data on NC181, a Novel Therapeutic Candidate Targeting ApoE4, for the Treatment of Alzheimer’s DiseaseSeptember 12, 2023 | finance.yahoo.comA Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in Combination with Pembrolizumab (NCT04699123) Demonstrates Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLCSeptember 7, 2023 | finance.yahoo.comNextCure and Nordic Bioscience Publish Review Article on the Regulation of Tumor Immunity by Tumor CollagenSeptember 5, 2023 | finance.yahoo.comPreclinical Data Demonstrate Potential Application of Anti-Siglec-15 Treatment in Bone DiseaseAugust 31, 2023 | finance.yahoo.comNextCure to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 8, 2023 | msn.comHC Wainwright & Co. Initiates Coverage of Nextcure (NXTC) with Buy RecommendationAugust 3, 2023 | finance.yahoo.comNextCure Provides Business Update and Reports Second Quarter 2023 Financial ResultsJune 21, 2023 | benzinga.comNextCure Presents Non-Clinical Data Defining The Mechanism Of NC525 At The 2023 Federation Of Clinical Immunology Societies Annual MeetingJune 21, 2023 | fool.comNextCure (NASDAQ: NXTC)June 21, 2023 | finance.yahoo.comNextCure Presents Non-Clinical Data Defining the Mechanism of NC525 at the 2023 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting Get NextCure News Delivered to You Automatically Sign up to receive the latest news and ratings for NXTC and its competitors with MarketBeat's FREE daily newsletter. Email Address The most important AI company you've never heard of (Ad)Because this small company solves the BIGGEST problem with Nvidia's AI chips. Already, Amazon, Microsoft, Google and others are lining up to get this company's products. Get the full story on this secret AI company poised for massive growth NXTC Media Mentions By Week NXTC Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NXTC News Sentiment▼1.870.55▲Average Medical News Sentiment NXTC News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NXTC Articles This Week▼11▲NXTC Articles Average Week Get NextCure News Delivered to You Automatically Sign up to receive the latest news and ratings for NXTC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: OCUP News Today HCWB News Today AADI News Today GANX News Today EYEN News Today CASI News Today VYNE News Today IMRX News Today UNCY News Today XLO News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NXTC) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersAmazon's betting big on this unknown AI companyManward PressThis Wall Street stock prediction just went viralChaikin AnalyticsTop 5 AI Stocks to Buy for 2024Market Moving TrendsThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportPharma Giant Makes Deal with a "Drug Smuggler"Behind the MarketsTop 5 Tech Stocks to Buy for 2024Daily Market Alerts Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NextCure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
